secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-06-15T13:21:02+00:00
Accession:  0001601485-26-000046
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Phase 2 AMPLIFY-7P misses primary DFS endpoint; positive R0 subgroup guides Phase 3
--------------------------------------------------------------------------------

- AMPLIFY-7P did not meet primary endpoint of DFS in ITT; R1 resection imbalance (19% vs 10%) favored observation arm.
- Post-hoc analysis in R0 patients showed HR 0.65 (p=0.048); mDFS 23.8 mo vs 12.8 mo; 84% of study population.
- mKRAS-specific T cell responses strongly correlated with DFS (HR 0.22, p<0.0001, n=90).
- Refined Phase 3 plan targets R0 resected patients with additional dosing; cash runway into Q4 2026; exploring financing.
- Favorable safety: no treatment-related discontinuations or deaths.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/0001601485-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/angn-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001601485-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer